Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Preliminary Study Suggests Possible New Treatment for MS

A small, preliminary study may show promise of a new type of treatment for progressive multiple sclerosis (MS). Results from the first six people enrolled in the phase 1 study, a study designed to enroll 10 people, are being presented at the American Academy of Neurology’s 69th Annual Meeting in Boston, April 22 to 28, 2017.

Science

Channels:

Bladder Cancer, bladder cancer clinical trial, bladder cancer metastasis, bladder, bladder cancer treatment, atezolizumab, FDA Approval, FDA, FDA Cleared, bladder tumor, checkpoint inhibitors

NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug

Arjun-Balar-Patient-8.jpg

Findings from a clinical trial led by a researcher at NYU Langone’s Perlmutter Cancer Center helped pave the way for the recent, accelerated approval by the U.S. Food and Drug Administration (FDA) of a highly effective immunotherapy as first line treatment for patients with advanced bladder cancer who are not eligible for treatment with standard chemotherapy

Medicine

Channels:

Clinical Trial, Clinical Trials

The Medical Minute: Healthy Volunteers Vital to Clinical Trials

doctor_patient_2.jpg

There is an ongoing need for healthy volunteers in clinical research studies that can lead to healthcare breakthroughs that provide better drugs and treatments for patients.

Medicine

Channels:

Peer Reviewed Publication Confirms the Absence of Rhabdovirus in Cell Line Used for Manufacturing of Flublok®

/PRNewswire/ -- Protein Sciences Corporation is pleased to announce the publication of its manuscript entitled "Complete Study Demonstrating the Absence of Rhabdovirus in a Distinct Spodoptera frugiperda (Sf9) Cell Line" in the peer-reviewed journal PLOS ONE, Volume 12 issue 4. The publication follows extensive testing of the parent cells from which Protein Sciences' proprietary expresSF+® (SF+) cell line is derived. The study confirms that a contaminating rhabdovirus previously reported in a related cell line is not present in SF+ cells. These results demonstrate that not all cell lines are equal even if they are derived from the same parent cell line and highlight the high quality of the SF+ cell lineage.

Medicine

Channels:

150-Year-Old Drug May Provide ‘Off’ Time Relief for People with Advanced Parkinson’s Disease

New research provides evidence that an old drug may provide relief for people with advanced Parkinson’s, according to a study released today that will be presented at the American Academy of Neurology’s 69th Annual Meeting in Boston, April 22 to 28, 2017.

Medicine

Channels:

Glioblastoma, Brain Cancer, Malaria, Chloroquine, University Of Colorado Cancer Center, jean mulcahy-levy

Malaria Drug Successfully Treats 26-Year-Old Brain Cancer Patient

Mulcahy.w.Patient.png

Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy

Medicine

Channels:

Malaria, Drug Delivery

Long-Lasting Drug Delivery System May Help Decrease the Spread of Malaria

F1.large.jpg

Researchers have developed a capsule that, when dissolved in the stomach, releases a star-shaped material containing drugs that help to prevent malaria infections and lasts for up to two weeks.

Medicine

Channels:

Asthma, COPD, chronic pulmonary disease, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, Cystic, pulmonary biology, molecular compound, tran, Nucleus, Clinical Trial, Science Signaling, American Association for the Advancement of Science, Cincinnati Children’s Hospital Medical Center, Pediatrics Diseases, press release distribution

Experimental Drug Targets Nucleus of Allergen-Sensitized Cells

Kalinichenko_SciSig_RCM-1asthmaEXT.jpg

Transcription factors, the tiny proteins that switch genes on or off in the nucleus of cells, are considered unreachable molecular targets for drugs attempting to treat medical conditions. Overcoming this challenge, researchers discovered a small molecular compound that successfully blocks a transcription factor and its pro-inflammatory and hyper-mucous activity in asthma. In a study published online April 18 by Science Signaling, scientists test a new compound they call RCM-1.

Science

Channels:

UCLA Scientists Combine a Peptide with a Nano Cancer Drug Formulation to Improve Treatment Effectiveness and Prevent Metastasis in Pancreatic Cancer

ShowImage.jpg

UCLA scientists have unlocked an important mechanism that allows chemotherapy-carrying nanoparticles—extremely small objects between 1 and 100 nanometers (a billionth of a meter)—to directly access pancreatic cancer tumors, thereby improving the ability to kill cancer cells and hence leading to more effective treatment outcome of the disease. The researchers also confirmed the key role of a peptide (an extremely small protein) in regulating vascular access of the nanoparticle to the cancer site.

Medicine

Channels:

Cachexia, Cancer, cancer advances, Wasting, Wasting Disease, Drug Trial, drug trials, Pilot Clinical Trial, Pilot Study, Pilot Clinical Trials, Pilot Program

Promising New Drug Development Could Help Treat Cachexia

According to the National Cancer Institute, nearly one-third of cancer deaths can be attributed to a wasting syndrome known as cachexia. Cachexia, an indicator of the advanced stages of disease, is a debilitating disorder that causes loss of appetite, lean body mass and can lead to multi-organ failure. Now, researchers at the University of Missouri in partnership with Tensive Controls, Inc. have developed a drug that could reverse cachexia. The team currently is seeking canine candidates for a pilot study to test the new drug.







Chat now!